Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

146.91 -1.29 (-0.87%)
Streaming Delayed Price Updated: 2:20 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
1 S&P 500 Stock Worth Investigating and 2 Facing Headwinds
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
From Zoetis Inc.
Via Business Wire
1 Cash-Producing Stock to Consider Right Now and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Analyst Expectations For Zoetis's Future
 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
How Do Investors Really Feel About Zoetis?
 
Via Benzinga
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Zoetis Inc.
Via Business Wire
2 Reasons to Watch ZTS and 1 to Stay Cautious
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next... 
Via StockStory
Topics Government Stocks World Trade
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
ZTS Q2 Deep Dive: Market Questions Librela Outlook Amid Double-Digit Growth in Core Franchises
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around... 
Via StockStory
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
From Zoetis Inc.
Via Business Wire
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one. 
Via The Motley Fool
3 Large-Cap Stocks with Promising Prospects
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns. 
Via The Motley Fool
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness. 
Via Benzinga
Zoetis Surges After Crushing Expectations And Raising Its Outlook
The company raised its adjusted profit guidance by 10 cents at the midpoint and hiked its sales guide by $25 million. 
Via Investor's Business Daily
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Discover the top S&P500 movers in Tuesday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Zoetis (NYSE:ZTS) Posts Better-Than-Expected Sales In Q2, Stock Soars
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue... 
Via StockStory
1 Top Dividend Growth Stock to Buy and Hold Forever
The demand for this company's products will continue increasing. 
Via The Motley Fool
Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook
From Zoetis Inc.
Via Business Wire
IDEXX Laboratories Soars: A New Benchmark for Animal Health Diagnostics
IDEXX Laboratories (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, has sent ripples through the financial markets with an astounding 27.5% surge in its stock price. This... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Zoetis (ZTS) Reports Earnings Tomorrow: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Tuesday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Billionaire Terry Smith Sold Fundsmith's Entire Stake in Apple and 11X'd His Position in a Company Whose Addressable Market Can Hit $149 Billion by 2032
The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher. 
Via The Motley Fool
Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?
Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Government Stocks World Trade
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Assessing Zoetis: Insights From 4 Financial Analysts
 
Via Benzinga
1 Cash-Producing Stock with Competitive Advantages and 2 to Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.